Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man
- PMID: 1069859
- DOI: 10.1093/jnci/57.6.1211
Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man
Abstract
To investigate the systemic, clinical and laboratory effects of iv polyriboinosinic-polyribocytidylic acid (poly I-poly C), 32 doses of poly I-poly C were administered to 22 patients. Doses between 1 and 10 mg/kg induced the formation of serum interferon (IF) and fever. Whereas a direct relationship was seen between the poly I-poly C dose and fever, serum IF levels were not significantly changed by increasing the dose of poly I-poly C over a log range from 1 to 10 mg/kg. Transient abnormalities were noted in liver function tests in 4 of 13 patients who received greater than 6.0 mg/kg. Other laboratory changes were confined to an increase in the absolute granulocyte count that paralleled fever development and abnormalities in coagulation parameters of 1 patient. In vitro lymphocyte DNA synthesis in response to mitogens was transiently impaired at times corresponding to serum IF appearance. These studies have established dose levels of poly I-poly C that can be safely administered to man with minimal toxicity and result in IF induction.
Similar articles
-
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors.J Natl Cancer Inst. 1976 Sep;57(3):599-602. doi: 10.1093/jnci/57.3.599. J Natl Cancer Inst. 1976. PMID: 978771
-
Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer.Cancer Res. 1979 May;39(5):1645-50. Cancer Res. 1979. PMID: 371793 Clinical Trial. No abstract available.
-
The fever induced by polyriboinosinic:polyribocytidylic acid is not related to interferon synthesis in the rabbit's hypothalamus.J Interferon Res. 1991 Jun;11(3):165-9. doi: 10.1089/jir.1991.11.165. J Interferon Res. 1991. PMID: 1717613
-
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.Antimicrob Agents Chemother. 1980 Jan;17(1):49-54. doi: 10.1128/AAC.17.1.49. Antimicrob Agents Chemother. 1980. PMID: 7352750 Free PMC article.
-
Interferon induction in cancer: with some observations on the clinical effects of poly 1:C.Med Clin North Am. 1971 May;55(3):721-8. doi: 10.1016/s0025-7125(16)32513-5. Med Clin North Am. 1971. PMID: 4932880 Review. No abstract available.
Cited by
-
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.Vaccines (Basel). 2022 May 22;10(5):819. doi: 10.3390/vaccines10050819. Vaccines (Basel). 2022. PMID: 35632575 Free PMC article. Review.
-
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.Breast Cancer Res. 2012 Mar 7;14(2):R39. doi: 10.1186/bcr3135. Breast Cancer Res. 2012. PMID: 22397502 Free PMC article.
-
Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.EMBO Mol Med. 2015 Apr 17;7(7):973-88. doi: 10.15252/emmm.201404525. Print 2015 Jul. EMBO Mol Med. 2015. PMID: 25888235 Free PMC article.
-
The interferon renaissance: molecular aspects of induction and action.Microbiol Rev. 1981 Jun;45(2):244-66. doi: 10.1128/mr.45.2.244-266.1981. Microbiol Rev. 1981. PMID: 6167846 Free PMC article. Review. No abstract available.
-
Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.Drugs. 1982 Jan-Feb;23(1-2):37-55. doi: 10.2165/00003495-198223010-00002. Drugs. 1982. PMID: 6173188 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous